Characteristic | Median no. |
Sex | |
Male | 9 (56) |
Female | 7 (44) |
Treatment | |
Pembrolizumab (clinical trial) | 15 (94) |
200 mg/2 wk (NCT01953692) | 8 (50) |
200 mg/3 wk (NCT02453594) | 7 (44) |
Nivolumab (compassionate) | 1 (6) |
3 mg/kg/2 wk | 1 (6) |
Age | 39 (range, 19–69) |
Delay since first diagnosis | 4.4 y (range, 0.6–14.8) |
Ann Arbor stage | |
Localized | 5 (31) |
I | 0 (0) |
IIA | 2 (13) |
IIB | 3 (19) |
Advanced | 11 (69) |
III | 1 (6) |
IV | 10 (63) |
Prior treatment | |
Previous lines of therapy* | 6 (range, 3–13) |
Chemotherapies | 16 (100) |
Targeted molecular agents | 5 (31) |
Autologous stem cell transplantation | 8 (50) |
Radiation therapy | 5 (31) |
↵* Excluding high-dose preparative regimen prior to autologous stem cell transplantation.
Data in parentheses are percentages, unless otherwise indicated.